Pharmacokinetics and pharmacodynamics of a new ACT formulation: Artesunate/Amodiaquine (TRIMALACT®) following oral administration in African malaria patients

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 34, Issue 3-4, 2009, Pages 133-142

  Sinou, V ^a   Malaika, Tshilolo Muepu ^b   Taudon, N ^a   Lwango, R ^b   Alegre, S Sese ^b   Bertaux, L ^a   Sugnaux, F ^c   Parzy, D ^a   Benakis, A ^d  

^a AIX MARSEILLE UNIVERSITY   (France)

^b Monkole Hospital Center   (Congo)

^c Sugnaux Scientific   (Switzerland)

^d UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

African patients; Amodiaquine; Artesunate; Pharmacodynamics; Pharmacokinetics; Plasmodium falciparum

Indexed keywords

AMODIAQUINE PLUS ARTESUNATE; CHLOROQUINE; DEETHYLAMODIAQUINE; DIHYDROARTEMISININ; FANSIDAR; TRIMALACT; UNCLASSIFIED DRUG;

ADULT; AFRICAN AMERICAN; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONGO; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; GENOTYPE; HAPLOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALARIA; MALARIA FALCIPARUM; MALE; PARASITEMIA; PEGANUM HARMALA; PHARMACODYNAMICS; PLASMODIUM FALCIPARUM; POINT MUTATION;

EID: 72149127131     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03191163     Document Type: Article

References (38)

1. World Health Organisation (2008). World Malaria Report 2008 WHO/HTM/MAL/2008.1. World Health Organisation, Geneva, Switzerland. http://www.who.int/malaria/wmr2008/.
2. World Health Organisation (2006a). Guidelines for the treatment of malaria. World Health Organisation, Geneva, Switzerland. WHO/HTM/MAL/2006.1108. http://www.who.int/malaria/docs/TreatmentGuidelines2006.pdf.
3. Sirima S.B., Gansané A. (2007). Artesunate-amodiaquine for the treatment of uncomplicated malaria. Expert Opin. Investig. Drugs, 16, 1079-1085.
4. World Health Organisation (2006b). Facts on ACTs (artemisinin-based combinations). World Health Organisation, Geneva, Switzerland. http://www.rollbackmalaria-org/cmc-upload/0/000/015/364/RBMInf osheet-9.pdf.
5. Wembonyama S., Mpaka S., Tshilolo L. (2007). Medicine and health in the Democratic Republic of Congo: from independence to the third republic, Med. Trop., 67, 447-457.
6. Kazadi W., Sexton J.D., Bigonsa M., W'Okanga B., Way M. (2004) Malaria in primary school children and infants in Kinshasa, Democratic Republic of the Congo: surveys from the 1980S and 2000. Am. J. Trop. Med., 71, 97-102.
7. Coene J. (1993). Malaria in urban and rural Kinshasa: the entomological input. Med. Vet. Entomol., 7, 127-137.
8. Bard B., Carrupt P.-A. (2008) Dissolution study of TRIMALACT. Expertise Report from the LTC-Pharmacochemistry Department Pharmaceutical Sciences Division, Geneva and Lausanne Universities.
9. Vo T.K., Bigot P., Gazin P., Sinou V., De Pina J.J., Huynh D.C., Fumoux F., Parzy D. (2007). Evaluation of a real-time PCR assay for malaria diagnosis in patients from Vietnam and in returned travellers. Trans. R. Soc. Trop. Med. Hyg, 101:422-428.
10. Reeder J.C., Rieckmann K.H., Genton B., Lorry K., Wines B., Cowman A.F. (1996). Point mutations in the dihydrofolate reductase and dihydropteroate synthetase genes and in vitro susceptibility to pyrimethamine and cycloguanil of Plasmodium falciparum isolates from Papua New Guinea. Am. J. Trop. Med. Hyg., 55, 209-213.
11. Parzy D., Doerig C., Pradines B., Rico A., Fusai T., Doury J.C. (1997). Proguanil resistance in Plasmodium falciparum African isolates: assessment by mutation-specific polymerase chain reaction and in vitro susceptibility testing. Am. J. Trop. Med. Hyg., 57, 646-650.
12. Djimbé A., Doumbo O.K., Cortese J.F., Kayentao K., Doumbo S., Diourté Y., Dicko A., Su X.Z., Nomura T., Fidock D.A., Wellems T.E., Plowe C.V., Coulibaly D. (2001). A molecular marker for chloroquine-resistant falciparum malaria. N. Engl. J. Med., 344, 299-302.
13. Bogreau H., Renaud F., Bouchiba H., Durand P., Assi S.-B., Henry M.-C., Garnotal E., Pradines B., Fusai T., Wade B., Adehossi E., Parola P., Ali Kamil M., Puijalon O., Rogier C. (2006). Genetic diversity and structur of African Plasmodium falciparum populations in urban and rural areas. Am. J. Trop. Med. Hyg., 74, 953-959.
14. Su X., Wellems T.E. (1996). Toward a high-resolution Plasmodium falciparum linkage map: polymorphic markers from hundreds of simple sequence repeats. Genomics, 33, 430-444. (Pubitemid 26159859)
15. Anderson T.J., Su, X.Z., Bockarie M., Lagog M., Day K.P. (1999). Twelve microsatellite markers for characterization of Plasmodium falciparum from finger-prick blood samples. Parasitology, 119, 113-125. (Pubitemid 29381128)
16. Mulumba P.M. (2002).Situation épidémiologique du paludisme en République Démocratique du Congo. Congo Médical, 5, 431-435.
17. Delacollette C., Embonga B., Malengreau M. (1983). Response to chloroquine of infections with Plasmodium falciparum in the Kivu region. Ann. Soc. Belg. Med. Trop., 53, 171-173.
18. World Health Organisation (2005). Susceptibility of Plasmodium falciparum to Antimalarial Drugs, Report on Global Monitoring 1996-2004. WHO/HTM/MAL/2005.1103. World Health Organisation, Geneva., Switzerland.
19. Cohuet S., Bonnet M., Van Herp M., Van Overmeir C., D'Alessandro U., Gluthmann J.-P. (2006). Short report : moleclar markers associated with Plasmodium falciparum resistance to sulfadoxine-pyrimethamine in the Democratic Republic of Congo, Am. J. Trop. Med. Hyg., 75, 152-154. (Pubitemid 351627585)
20. Swarthout T.D., van den Broek I.V., Kayembe G., Montgomery J., Pota H., Roper C. (2006). Artesunate + amodiaquine and artesunate + sulfadoxine- pyrimethamine for treatment of uncomplicated malaria in Democratic Republic of Congo: a clinical trial with determination of sulfadoxine and pyrimethamine-resistant haplotypes. Trop. Med. Int. Health, 11, 1503-1511.
21. Alker A.P., Kazadi W.M., Kutelemeni A.K., Bloland P.B., Tshefu A.K., Meshnick S.R. (2008). dhfr and dhps genotype and sulfadoxine-pyrimethamine treatment failure in children with falciparum malaria in the Democratic Republic of Congo. Trop. Med. Int. Health, 11, 1384-1391.
22. Peters P.J., Thigpen M.C., Parise M.E., Newman R.D. (2007). Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment. Drug. Saf., 30, 481-501.
23. Omar S.A. Adagu I.S., Wharhust D.C. (2001). Can pretreatment screening for dhps and dhfr point mutations in Plasmodium falciparum infections be used to predict sulfadoxine-pyrimethamine treatment failure? Trans. R. Soc. Trop. Med. Hyg., 95, 315-319.
24. Kublin J.G., Dzinjalamala F.K., Kamwendo D.D., Malkin E.M., Cortese J.F., Martino L.M., Mukadam R.A., Rogerson S.J., Lescano A.G., Molyneux M.E., Winstanley P.A., Chimpeni P., Taylor T.E., Plowe C.V. (2002). Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. J. Infect. Dis., 185, 380-388.
25. Staedke S.G., Sendagire H., Lamola S., Kamya M.R., Dorsey G., Rosenthal P.J. (2004). Relationship between age, molecular markers, and response to sulphadoxinepyrimethamine treatment in Kampala, Uganda. Trop. Med. Int. Health, 9, 624-629.
26. Gesase S., Gosling R.D., Hashim R., Ord R., Naidoo I., Madebe R., Mosha J.F., Joho A., Mandia V., Mrema H., Mapunda E., Savael Z., Lemnge M., Mosha F.W., Greenwood B., Roper C., Chandramohan D. 2009. High resistance of Plasmodium falciparum to Sulphadoxine/Pyrimelhamine in Northern Tanzania and the emergence of dhps resisatnce mutation at codon 581. PloS ONE, 4: e4569. doi:10.1371/journal.pone.0004569.
27. Wilson P.E., Kazadi W., Demster Kamwendo D., Mwapasa V., Purfield A., Meshnick S.R. (2005). Prevalence of pfcrt mutations in Congolese and Malawian Plasmodium falciparum isolates as determined by a new Taqman assay. Acta Trop., 93, 97-106. (Pubitemid 39611359)
28. Adjuik M., Agnamey P., Babiker A., Borrmann S., Brasseur P., Cisse M., Cobelens F., Diallo S., Faucher J.F., Garner P., Gikunda S., Kremsner P.G., Krishna S., Lell B., Loolpapit M., Matsiegui P.-B., Missinou M.A., Mwanza J., Ntoumi F., Olliaro P., Osimbo P., Rezbach P., Some E., Taylor W.R.J. (2002). Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomized, multicentre trial. Lancet, 359, 1365-1371
29. Barennes H., Nagot N., Valea I., Koussoubé-Balima T., Ouedraogo A., Sanou T., Yé S. (2004). A randomized trial of amodiaquine and artesunate alone and in combination for the treatment of uncomplicated falciparum malaria in children from Burkina Faso. Trop. Med. Int. Health, 9, 438-444.
30. Sowunmi A., Fehintola F.A;, Adedeji A.A., Gbotosho G.O., Tambo E., Fateye B.A., Happi T.C., Oduola A.M.J. (2005). Open randomized study of artesunate-amodiaquine vs. chloroquine-pyrimethamine-sulfadoxine for the treatment of uncomplicated Plasmodium falciparum malaria in Nigerian children. Trop. Med. Int. Health, 10, 1161-1170.
31. Benakis A., Pains M., Anh T.K., Binh T.Q., Plessas C.T., Plessas S.T. (1996). Pharmacokinetic study of dihydroartemisinin in malaria patients in Vietnam. Jpn J. Trop. Med. Hyg. 24, 71-76.
32. Benakis A., Paris M, Loutan L. Plessas C.T., Plessas S.T. (1997). Pharmacokinetics of artemisinin and artesunate after oral administration in healthy volunteers. Am. J. Trop. Med. Hyg., 56, 17-23.
33. Halpaap B., Ndjave M., Paris M., Benakis A., Kremsner P.G. (1998) Plasma levels of artesunate and dihydroanemisinin in children with Plasmodium falciparum malaria in Gabon after administration of 50-milligram artesunate suppositories. Am. J. Trop. Med. Hyg. 58, 365-368.
34. Sinou V., Taudon N., Mosnier J., Aglioni C., Bressolle F.M., Parzy D. (2008). Pharmacokinetics of artesunate in the domestic pig. J. Antimicrob.Chemother., 62, 566-574.
35. Pussard E., Verdier F., Faurisson F., Scherrmann J.M., Le Bras J., Blayo M.C. (1987). Disposition of monodesethylamodiaquine after a single oral dose of amodiaquine and three regimens for prophylaxis against Plasmodium falciparum malaria. Eur. J. Clin. Pharmacol., 33, 409-414.
36. Winstanley P.A., Edwards G., Orme M.L., Breckenridge A.M. (1987). Effect of dose size on amodiaquine pharmacokinetics after oral administration. Eur. J. Clin. Pharmacol., 33, 331-333.
37. Navaratnam V., Ramanathan S., Wahab M.S. A., Siew Hua G., Mansor S.M., Kiechel J.-R., Vaillant M., Taylor W.R.J., Olliaro P. (2009). Tolerability and pharmacokinetics of non- fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers. Eur. J. Clin. Pharmacol., 65, 809-821.
38. Orrell C., Little F., Smith P., Folb P., Taylor W., Olliaro P., Barnes K.I. (2008). Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers. Eur. J. Clin. Pharmacol., 64, 683-690.